Overview

Utilization of a Microdevice for Psoriasis and Atopic Dermatitis

Status:
NOT_YET_RECRUITING
Trial end date:
2030-06-01
Target enrollment:
Participant gender:
Summary
This study is being done to test a microdevice, which is a small device designed to test drugs directly on skin conditions like atopic dermatitis (eczema) and psoriasis. The small device, about the size of a grain of rice, has up to 20 tiny reservoirs that hold medications that are approved by the Food and Drug Administration (FDA) for atopic dermatitis and psoriasis. Very small amounts of these medications will be released into the skin (at levels in your body much lower than are typically used). In this study, the device will be tested to see if it's safe and works well for predicting how the skin will react to standard treatments. We will also look at how these reactions are connected to genetic information and overall treatment results.
Phase:
PHASE4
Details
Lead Sponsor:
University of California, San Francisco
Treatments:
abrocitinib
Adalimumab
apremilast
Azathioprine
bimekizumab
calcipotriene
Certolizumab Pegol
Chloroquine
crisaborole
Cyclosporine
deucravacitinib
dupilumab
Etanercept
Fluorouracil
guselkumab
Hydroxychloroquine
Infliximab
ixekizumab
lebrikizumab
Methotrexate
Mycophenolic Acid
nemolizumab
risankizumab
Roflumilast
ruxolitinib
secukinumab
Tacrolimus
tapinarof
tildrakizumab
tofacitinib
tralokinumab
Triamcinolone
upadacitinib
Ustekinumab